Literature DB >> 8972242

Oral antidiabetic drug use in the elderly.

R Bressler1, D G Johnson.   

Abstract

Non-insulin-dependent diabetes mellitus (NIDDM) is a metabolic disease that is common in the elderly, and is characterised by insulin insufficiency and resistance. Measures such as bodyweight reduction and exercise improve the metabolic defects, but pharmacological therapy is the most frequently used and successful therapy. The sulphonylureas stimulate insulin secretion. Metformin and troglitazone increase glucose disposal and decrease hepatic glucose output without causing hypoglycaemia. Acarbose is a dietary aid that spreads the dietary carbohydrate challenge to endogenous insulin over time. These pharmacological agents, either alone or in combination, should improve blood glucose regulation in patients with NIDDM.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8972242     DOI: 10.2165/00002512-199609060-00005

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  216 in total

1.  Long-term comparative trial of glibenclamide and chlorpropamide in diet-failed, maturity-onset diabetics.

Authors:  B F Clarke; I W Campbell
Journal:  Lancet       Date:  1975-02-01       Impact factor: 79.321

2.  Drug interactions and long-term antidiabetic therapy.

Authors:  A W Logie; D B Galloway; J C Petrie
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

3.  Which comes first in non-insulin-dependent diabetes mellitus: insulin resistance or beta-cell failure? Both come first.

Authors:  G C Weir
Journal:  JAMA       Date:  1995-06-21       Impact factor: 56.272

4.  Alpha-glucoside hydrolase inhibition in diabetes.

Authors:  H Vierhapper; A Bratusch-Marrain; W Waldhäusl
Journal:  Lancet       Date:  1978 Dec 23-30       Impact factor: 79.321

Review 5.  Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.

Authors:  B Holmes; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

6.  The effects of the alpha-glucosidase inhibitor BAY g 5421 (Acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: dose-time-response relationships in man.

Authors:  I Hillebrand; K Boehme; G Frank; H Fink; P Berchtold
Journal:  Res Exp Med (Berl)       Date:  1979-04-23

7.  Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD.

Authors:  J Noury; A Nandeuil
Journal:  Diabete Metab       Date:  1991-05

8.  Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. A study in normal rats using chronic in vivo glucose infusions.

Authors:  J L Leahy; H E Cooper; D A Deal; G C Weir
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

9.  The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus.

Authors:  W T Garvey; J M Olefsky; J Griffin; R F Hamman; O G Kolterman
Journal:  Diabetes       Date:  1985-03       Impact factor: 9.461

10.  Sucrose malabsorption in man after ingestion of alpha-glucosidehydrolase inhibitor.

Authors:  W F Caspary
Journal:  Lancet       Date:  1978-06-10       Impact factor: 79.321

View more
  3 in total

Review 1.  Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.

Authors:  L J Scott; C M Spencer
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 2.  Troglitazone: a review of its use in the management of type 2 diabetes mellitus.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

Review 3.  Update on the treatment of type 2 diabetes mellitus.

Authors:  Juan José Marín-Peñalver; Iciar Martín-Timón; Cristina Sevillano-Collantes; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2016-09-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.